98%
921
2 minutes
20
Thymoma is the most common tumor of the anterior mediastinum. Routine imaging methods such as computed tomography or magnetic resonance imaging often lead to misdiagnosis between thymoma and other thymic abnormalities. Therefore, urgently needed is to develop a new diagnostic strategy. Here we identify interleukin-8 (IL-8) as a biomarker for auxiliary diagnosis of thymoma. We find that IL-8 levels in naïve T cells are markedly elevated in patients with thymoma compared to those with other thymic tumors. IL-8 levels in naive T cells are significantly decreased after surgical resection in thymoma patients, and rise again when thymoma recurs. A receiver operating characteristic curve analysis shows that IL-8 evaluation performs well in thymoma identification, with high specificities and sensitivities. We also observe significant clinical relevance between IL-8 levels in naïve T cells and clinicopathological features. In conclusion, our study suggests that IL-8 is a biomarker for thymoma identification and recurrence surveillance.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522267 | PMC |
http://dx.doi.org/10.1038/s41467-020-18697-x | DOI Listing |
Front Immunol
July 2025
Department of Oncology, Hebei Medical University, Shijiazhuang, Hebei, China.
[This corrects the article DOI: 10.3389/fimmu.2025.
View Article and Find Full Text PDFSurg Case Rep
July 2025
Department of Thoracic Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Introduction: Thymomas have the potential to locally invade and metastasize, occasionally infiltrating adjacent structures, such as the great vessels and the heart. Although direct extension is the primary mechanism of vascular invasion, rare cases of intravascular growth have also been reported.
Case Presentation: We present the case of a 50-year-old woman diagnosed with a thymoma that extended intraluminally into the left brachiocephalic vein (LBCV), forming a tumor thrombus.
Front Immunol
August 2025
Department of Oncology, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Thymoma is often associated with myasthenia gravis (MG), and the resection of thymoma improves myasthenic symptoms in patients with thymoma and MG (TMG), but some patients still have no relief. Through proteomic analysis, we examined preoperative serum samples from patients with TMG to identify key prognostic proteins that could serve as a foundation for clinically predicting postoperative efficacy and guiding treatment selection.
Method: According to the Clinical Research Guidelines of the Myasthenia Gravis Foundation of America (MGFA) for Post-Intervention Status (PIS), 20 patients with TMG were divided into an effective group (T1) [the PIS was minimal manifestation status (MMS) and above] and an ineffective group (T2) (the PIS did not reach MMS and above), with 10 cases each, and a healthy control group (C) with nine cases.
Clin Chim Acta
September 2025
Department of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China. Electronic address:
Background And Aim: The identification of serum antibodies, particularly acetylcholine receptor antibodies (AChR-ab), is essential for diagnosing myasthenia gravis (MG). However, the clinical significance of blocking AChR-abs (bAChR-ab) and their correlation with disease severity remain underexplored. This study aims to evaluate the distribution of bAChR-ab across MG subtypes and their correlation with clinical severity.
View Article and Find Full Text PDFMed
June 2025
Division of Medical Oncology, Humanitas Gavazzeni, Bergamo, Italy. Electronic address:
In this issue of Med, Möhrmann et al. present a comprehensive analysis of 81 advanced thymic epithelial tumors (TETs). The study offers insights into the tumor mutational landscape, germline alterations, and the identification of different immunological subsets.
View Article and Find Full Text PDF